Stockreport

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology [Read more]